Genscript Biotech Corporation (G51) — Capital Reinvestment Ratio
Genscript Biotech Corporation (G51) has a Capital Reinvestment Ratio of 0.26x as of December 2025, meaning it reinvests 0% of its operating cash flow (€325.52 Million) in capital expenditures (€83.84 Million). See Genscript Biotech Corporation (G51) net asset quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Genscript Biotech Corporation Capital Reinvestment Ratio (2016–2025)
This chart tracks Genscript Biotech Corporation's Capital Reinvestment Ratio across 5 annual periods. Check Genscript Biotech Corporation total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Genscript Biotech Corporation (2016–2025)
Year-by-year Capital Reinvestment Ratio for Genscript Biotech Corporation from 2016 to 2025. For live market cap and broader valuation context, see Genscript Biotech Corporation (G51) total market value.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.26x | €325.52 Million | €83.84 Million | ▼ -86.8% |
| 2024 | 1.96x | €75.65 Million | €147.92 Million | ▲ +749.2% |
| 2018 | 0.23x | €307.66 Million | €70.84 Million | ▼ -83.2% |
| 2017 | 1.37x | €21.37 Million | €29.21 Million | ▲ +406.6% |
| 2016 | 0.27x | €33.27 Million | €8.98 Million | — |